Skip to main content

Table 2 Results of univariate analyses showing relationships between clinicopathological characteristics and lymph node metastases

From: Clinicopathological characteristics and treatment strategies in early gastric cancer: a retrospective cohort study

Variables pT1a tumor
(n = 161)
pT1b1 tumor
(n = 43)
pT1b2 tumor
(n = 123)
  pN(+) p-value pN(+) p-value pN(+) p-value
Total 4/161 (2.5%)   4/43 (9.3%)   37/123 (30.1%)  
   Sex   0.6269   0.2802   0.8309
   Male 3/88 (3.4%)   4/28 (14.3%)   26/88 (29.6%)  
   Female 1/73 (1.4%)   0/15   11/35 (31.4%)  
Age   0.6332   0.3449   0.8432
   < 65 3/91 (3.3%)   3/21 (14.3%)   16/51 (31.4%)  
   65 ≤ 1/70 (1.4%)   1/22 (4.6%)   21/72 (29.2%)  
Main tumor site   0.1903   0.2707   0.1129
   Upper 0/19   0/3   3/21 (14.3%)  
   Middle 4/89 (4.5%)   4/27 (14.8%)   17/59 (28.8%)  
   Lower 0/53   0/13   17/43 (39.5%)  
Clinical macro type   0.5655   0.5579   0.4764
   Depressed or excavated 3/131 (2.3%)   4/33 (12.1%)   27/96 (28.1%)  
   Flat or elevated 1/30 (3.3%)   0/10   10/27 (37.0%)  
Pathological macro type   1.0000   1.0000   0.4764
   Depressed 4/139 (2.9%)   4/37 (10.8%)   27/96 (28.1%)  
   Flat or elevated 0/22   0/6   10/27 (37.0%)  
Ulceration   0.1287   0.3235   0.4200
   No 0/72   1/23 (4.4%)   21/77 (27.3%)  
   Yes 4/89 (4.5%)   3/20 (15.0%)   16/46 (34.8%)  
Main histologic type   0.1252   0.4672   0.8441
   Differentiated 0/74   2/29 (6.9%)   19/66 (28.8%)  
   Undifferentiated 4/87 (4.6%)   2/14 (14.3%)   18/57 (31.6%)  
Pathological tumor size   1.0000   1.0000   0.0589
   ≤20 mm 1/60 (1.7%)   0/7   4/28 (14.3%)  
   20 mm< 3/101 (2.5%)   4/36 (11.1%)   33/95 (34.7%)  
Pathological tumor size   0.3083   1.0000   0.1730
   ≤30 mm 1/96 (1.0%)   2/21 (9.5%)   13/55 (23.6%)  
   30 mm< 3/65 (4.6%)   2/22 (9.1%)   24/68 (35.3%)  
Lymphatic invasion   0.0731   0.5227   < 0.0001**
   L0 3/158 (1.9%)   3/36 (8.3%)   4/52 (7.7%)  
   L1-2 1/3 (33.3%)   1/7 (14.3%)   33/71 (46.5%)  
Venous invasion   1.0000   1.0000   0.4200
   V0 4/160 (2.5%)   4/42 (9.5%)   21/77 (27.3%)  
   V1-3 0/1   0/1   16/46 (34.8%)  
  1. ** p < 0.01.
  2. According to the seventh edition of the International Union Against Cancer TNM guidelines [3].